Sutro Biopharma (STRO) Payables (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Payables data on file, last reported at $7.6 million in Q4 2025.

• For the quarter ending Q4 2025, Payables fell 27.78% year-over-year to $7.6 million; the trailing twelve-month figure through Dec 2025 stood at $7.6 million (down 27.78% YoY), and the FY2025 full-year result was $7.6 million, down 27.78% from the prior year.
• Payables advanced to $7.6 million in Q4 2025, from $7.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $12.6 million in Q2 2022 to a low of $3.9 million in Q2 2023.
• A 5-year average of $7.6 million and a median of $7.3 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables jumped 129.0% in 2021 and sank 69.32% in 2023, its largest moves.
• Tracing STRO's Payables over 5 years: stood at $6.0 million in 2021, then fell by 20.17% to $4.8 million in 2022, then soared by 96.79% to $9.4 million in 2023, then grew by 10.96% to $10.5 million in 2024, then decreased by 27.78% to $7.6 million in 2025.
• Business Quant data shows STRO's Payables at $7.6 million in Q4 2025, $7.0 million in Q3 2025, and $4.3 million in Q2 2025.